Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 2;20(7):e0326210.
doi: 10.1371/journal.pone.0326210. eCollection 2025.

GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine

Affiliations
Review

GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine

Zaher Merhi et al. PLoS One. .

Abstract

Background: The injectable glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drugs are commonly used for weight loss among reproductive-aged women but the perception of their impact on fertility is not clear among the public.

Objectives: The purpose of this review was to compare scientific literature to social media discourse and online search pertaining to the potential impact of GLP-1 RAs on female fertility.

Methods: Group 1 included 3 social media platforms, each of which required a different data collection method. For Reddit, VADER (Communalytic ®) was used as a sentiment analyzer and for Twitter and TikTok, we performed a manual search for posts and scored them using an objective internal scale. Group 2 included the online search engine Google Trends. Group 3 consisted of medical literature search by PubMed. All sentiments of posts/comments/articles were graded as: "Positive, Neutral, or Negative" and compared among groups.

Results: In Groups 1 and 2, scores showed a significantly more Positive than Neutral, and more Neutral than Negative sentiments. In Group 3, among the 52 original studies found on PubMed in women with polycystic ovary syndrome (PCOS), they all had Positive sentiments. In Groups 1, 2, and 3, there was a strong positive correlation among all sentiments (r2 = 0.83). Even though all 3 social media platforms had the majority of posts with a Positive sentiment and correlated with Google Trends posts and with PubMed studies in women with PCOS (r2 = 0.74), there was a lack of PubMed studies pertaining to the effect of GLP-1 RA in women without PCOS.

Conclusion: The Positive sentiments among women without PCOS is not justified by evidence-based medicine and there is a clear need for studies pertaining to this topic.

PubMed Disclaimer

Conflict of interest statement

NO authors have competing interests

Similar articles

References

    1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56. - PubMed
    1. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394–407. doi: 10.1056/NEJMoa2313917 - DOI - PubMed
    1. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:839–48. - PubMed
    1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183 - DOI - PubMed
    1. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971–84. - PubMed

Substances